Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
OPOpGen, Inc. logo

OpGen, Inc. (OPGN)

Other OTC · Currency in USD
$23.91 ▲ +9.75 (+64.36%)
At close: Mar 19, 9:30 AM ET. Market closed.

Summary

Previous Close
$23.91
Open
$23.91
Day's Range
$23.91 – $23.91
52 Week Range
$0.00 – $34.00
Volume
1,283
Avg. Volume
5,583
Market Cap
$242.67M
Beta (5Y Monthly)
-1.93
PE Ratio (TTM)
4.45
EPS (TTM)
$5.03
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$0.67

Profile: OpGen, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
85
CEO
Christian-Laurent Benoit Bonte
Website
opgen.com

OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U.S. and international markets. Its comprehensive product suite includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed to pinpoint various bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR) from bacterial colonies sourced from diverse specimen types. The company also offers Curetis CE-IVD-marked polymerase chain reaction (PCR)-based test kits for SARS-CoV-2 detection.

Earnings

DateEst.Actual
Nov 19, 2025–-$0.06
Aug 21, 2025-$1.40$0.83Beat
Nov 15, 2024-$1.60$1.35Beat
Aug 19, 2024-$1.70-$1.18Beat
Jul 8, 2024-$1.90$0.21Beat
Jun 3, 2024-$0.90-$2.52Miss

Analyst view

Consensus price target
$0.67 ▼ -97.2%
Range $0.67 – $0.67
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on OPGN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.